Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

<p>Abstract</p> <p>Background</p> <p>Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-speci...

Full description

Bibliographic Details
Main Authors:	Bedognetti Davide, Di Pasquale Giovanni, Roychoudhuri Rahul, Pos Zoltan, Chen Nanhai G, Adams Sharon, Reinboth Jennifer, Yu Zhiya, Worschech Andrea, Ascierto Maria, Uccellini Lorenzo, Rossano Fabio, Ascierto Paolo A, Stroncek David F, Restifo Nicholas P, Wang Ena, Szalay Aladar A, Marincola Francesco M
Format:	Article
Language:	English
Published:	BMC 2011-10-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/11/451

Similar Items

Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
by: Liu Hui, et al.
Published: (2009-07-01)

Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells
by: Wang Huiqiang, et al.
Published: (2012-08-01)

Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.
by: Ulrike Donat, et al.
Published: (2012-01-01)

Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.
by: Ivaylo Gentschev, et al.
Published: (2011-01-01)

Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.
by: Marion Adelfinger, et al.
Published: (2014-01-01)

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
by: Sandeep S Patil, et al.
Published: (2012-01-01)

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy
by: Marion Adelfinger, et al.
Published: (2015-07-01)

Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice
by: Yu Yong A, et al.
Published: (2011-09-01)

The stable traits of melanoma genetics: an alternate approach to target discovery
by: Spivey Tara L, et al.
Published: (2012-04-01)

Oncolytic vaccinia therapy of squamous cell carcinoma
by: Yu Yong A, et al.
Published: (2009-07-01)

Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
by: Ting Huang, et al.
Published: (2015-01-01)

Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy
by: Dana Haddad, et al.
Published: (2016-01-01)

Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.
by: Ivaylo Gentschev, et al.
Published: (2012-01-01)

Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
by: Schäfer Simon, et al.
Published: (2012-08-01)

An immunologic portrait of cancer
by: Stroncek David F, et al.
Published: (2011-08-01)

Intratumoral INF-Î³ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer
by: Christina Kober, et al.
Published: (2015-01-01)

HLA class I and II genotype of the NCI-60 cell lines
by: Morse Herbert C, et al.
Published: (2005-03-01)

Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter.
by: Dana Haddad, et al.
Published: (2012-01-01)

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
by: Wang Ena, et al.
Published: (2011-10-01)

Stabilization of the GLV System with Asymptotically Unbounded External Disturbances
by: Zhi Liu, et al.
Published: (2023-10-01)

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis
by: Delogu Lucia, et al.
Published: (2011-10-01)

Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus
by: Mittra Arjun, et al.
Published: (2011-03-01)

Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains.
by: Huiqiang Wang, et al.
Published: (2013-01-01)

Efficient Selection of Recombinant Fluorescent Vaccinia Virus Strains and Rapid Virus Titer Determination by Using a Multi-Well Plate Imaging System
by: Mingyu Ye, et al.
Published: (2021-08-01)

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
by: Boris R. Minev, et al.
Published: (2019-08-01)

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
by: Dobrin D. Draganov, et al.
Published: (2019-03-01)

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
by: Desislava Tsoneva, et al.
Published: (2017-06-01)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
by: Paolo A. Ascierto, et al.
Published: (2015-02-01)

Combination therapy: the next opportunity and challenge of medicine
by: Marincola Francesco M, et al.
Published: (2011-07-01)

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
by: Dobrin D. Draganov, et al.
Published: (2021-10-01)

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas
by: Ivan Petrov, et al.
Published: (2020-07-01)

Ready-made short basis for GLV+GLS on high degree twisted curves
by: Bei Wang, et al.
Published: (2022-01-01)

Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy
by: Sturm Julia B, et al.
Published: (2012-01-01)

Evolution of RGF/GLV/CLEL Peptide Hormones and Their Roles in Land Plant Growth and Regulation
by: Yitian Fang, et al.
Published: (2021-12-01)

Development of a <it>Bacillus subtilis </it>expression system using the improved P<it>glv </it>promoter
by: Ming Yang M, et al.
Published: (2010-07-01)

GM-CSF/IL-3/IL-5 receptor common β chain (CD131) expression as a biomarker of antigen-stimulated CD8<sup>+ </sup>T cells
by: Maric Dragan, et al.
Published: (2008-04-01)

Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
by: Stephen eThorne
Published: (2014-06-01)

Theranostic Potential of Oncolytic Vaccinia Virus
by: Juan J Rojas, Steve H Thorne
Published: (2012-01-01)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
by: Cao-Sang Truong, et al.
Published: (2022-02-01)